Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 13 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Certolizumab pegol improves mucosal lesions in ileocolonic Crohn's disease

The latest issue of Gut reports endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.

News image


Dr Xavier Hébuterne from France evaluated the efficacy of certolizumab pegol (CZP) in improving endoscopic lesions in patients with active ileocolonic Crohn's disease.

The team performed a phase IIIB multicenter open-label clinical trial, and enrolled 89 adult patients with active endoscopic disease.
 
Patients received subcutaneous certolizumab pegol 400 mg at weeks 0, 2 and 4, and every 4 weeks up to week 52. 

The researchers found that endoscopic evaluations were performed at weeks 0, 10 and 54. 

The team's primary outcome was mean change in CDEIS score at week 10.
 
Secondary outcome measures included endoscopic response, complete remission and mucosal healing at weeks 10 and 54.
Endoscopic response at week 10 was 54%
Gut
The team of doctors observed that the mean CDEIS score was 15 at baseline.
 
The researchers noted that the mean decrease in CDEIS score at week 10 was 6. 

Rates of endoscopic response, endoscopic remission, complete endoscopic remission and mucosal healing at week 10 were 54%, 37%, 10% and 4%, respectively. 

The researchers found that that at week 54 the corresponding rates were 49%, 27%, 14% and 8%, respectively. 
 
The safety profile was consistent with that of previous certolizumab pego trials.
 
Dr Xavier and team concludes, "Following certolizumab pego treatment in patients with active Crohn's disease, endoscopic lesions were improved as shown by the decrease in mean CDEIS score and by endoscopic response and remission rates."
 
"These benefits were achieved as early as week 10 and were generally maintained through week 54."

Gut 2013;62:201-208 
11 January 2013

Go to top of page Email this page Email this page to a colleague

 12 February 2016 
Colorectal cancer after negative signoidoscopy
 12 February 2016 
Genetic factors and response to glucocorticoids in IBD
 12 February 2016 
Tobacco smoking and the natural history of Crohn’s
 11 February 2016 
Colorectal surgery training
 11 February 2016 
Liver disease unique to pregnancy
 11 February 2016 
Serous cystic neoplasm 
 10 February 2016 
NAFLD in Veterans in the USA
 10 February 2016 
Rectosigmoidoscopy vs colonoscopy in ulcerative colitis
 10 February 2016 
Liver cancer and primary biliary cirrhosis
 09 February 2016 
Bowel preparation for colonoscopy screening
 09 February 2016 
Eosinophilic esophagitis and parental allergies
 09 February 2016 
Cancer-specific prognosis in octogenarians with colorectal cancer
 08 February 2016 
Cancelled colonoscopy appointments
 08 February 2016 
Cognitive function in Crohn's disease
 08 February 2016 
Immunity in the human gut
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Methotrexate and remission in ulcerative colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Managing HBV in pregnancy
 01 February 2016 
Depressive symptoms in IBD 
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us